Patent Grant
7759060
The present invention relates to diagnosis methods and, more particularly, to diagnosis methods for detecting prostate cancer.
Prostate cancer is a leading cancer in men with 20,100 new cases expected in Canada in 2004 (Canadian Cancer Statistics, 2004). An even larger number of patients, following a positive PSA (prostate specific antigen) reading undergo an invasive biopsy but are not diagnosed with cancer. Unfortunately, invasive biopsy procedures require a long hospitalization with many possible side-effects. The reason for using the more invasive biopsy procedure, as opposed to the less invasive core needle biopsy is that the standard diagnostic procedure on core needle biopsy samples has not been proven to be as accurate as a more invasive biopsy and was thereby discarded as a diagnostic modality in several countries. Although the more invasive biopsies may provide a more accurate diagnosis, they are extremely traumatic for the patient. Moreover, such procedures can potentially result in long term disabilities and constitutes a significant cost to the health system.
Current diagnostic techniques for detecting prostate cancer is based on the PSA level in the serum. The final diagnosis is determined by a pathologist checking for cancer cells in the biopsy samples.
However, these present techniques are not perfect. The PSA level in the serum can be affected by factors other then cancer, including other pathologies and age. In addition, specific properties of PSA protein in serum make accurate concentration measurements very difficult. As a result, the PSA test has a large percentage of false positive as well as false negative readings. Therefore, biopsy samples are essential for more accurate diagnosis. Unfortunately, as noted above, the preferred method of biopsy, the core needle biopsy, is often inaccurate due to the very small sample size. However, genetic testing in core needle biopsy samples will allow for the accurate diagnosis without the need for more invasive methods.
There is therefore a need for a more accurate diagnostic method that does not require an invasive biopsy to detect or diagnose prostate cancer. Ideally, such a method should be usable even with very small sample sizes and may be combined with other, pathologist-based diagnosis methods.
The present invention provides methods for diagnosing or detecting cancerous prostate tissue. A panel of 8 specific marker genes are provided. The overexpression of some of these marker genes compared to their expression in normal prostate tissue and the underexpression of the rest of these marker genes are indicative of cancerous prostate tissue. By using these 8 marker genes as a diagnostic tool, smaller tissue samples, such as those obtained by core needle biopsies can be used.
In a first aspect, the present invention provides a method for determining if prostate cells are cancerous, the method comprising:
a) obtaining said prostate cells;
b) determining if at least one specific gene is overexpressed or underexpressed in said prostate cells compared to an expression of said at least one specific gene in normal prostate cells;
c) determining that said prostate cells are cancerous based on whether said at least one gene is overexpressed or underexpressed in said prostate cells.
In another aspect, the present invention provides a use of at least one marker gene for identifying cancerous prostate tissue, an overexpression or underexpression of said at least one marker gene in prostate tissue compared to an expression of said at least one marker gene in normal prostate tissue being indicative of cancerous prostate tissue.
Yet another aspect of the invention provides a method of diagnosing prostate cancer, the method comprising:
a) obtaining prostate tissue to be diagnosed;
b) determining if specific marker genes are overexpressed or underexpressed in said prostate tissue to be diagnosed compared to non-cancerous prostate tissue;
c) determining if said prostate tissue to be diagnosed is cancerous based on an underexpression or overexpression of said specific marker genes.
A better understanding of the invention will be obtained by considering the detailed description below, with reference to the following drawings in which:
The present invention relates to the use of a panel of 8 specific marker genes to diagnose or detect cancerous prostate tissue. The panel of 8 marker genes are listed in Table 1 below. Experiments have shown that this panel of marker genes give high accuracy in prostate cancer diagnosis due to the expression levels of the marker genes in cancer tissue relative to their expression levels in normal tissue.
The panel of 8 marker genes is given in Table 1. The marker genes were determined using a method developed by the inventors from the prostate tissues (normal and cancer) gene expression dataset obtained and described by Singh, D. et al. (Singh, D. et al. Gene expression correlates of clinical prostate cancer behaviour. Cancer Cell 1:203 (2002)).
The genes listed above were derived using a microarray gene expression experiment, the gene expression plot being provided as
The dataset used for the experiments which resulted in the expression levels shown in the boxplots of
Referring to
As can be seen from
Referring to
The results illustrated in
Referring to
The results in
Referring to
The results in
Referring to
Referring to
Referring to
Referring to
From
The qualitative agreement between the differences in expression in cancer and normal prostate tissues for the eight genes investigated here is good overall with most genes showing significant difference between cancer and normal tissue as well as benign and malignant tumours in the majority of experiments. The results shown here prove that a subset of 8 genes is an appropriate diagnostic panel regardless of the experimental conditions. At the same time, in some cases, especially for the gene LTPB4, there are changes in the relative expression in cancer against normal prostate tissue depending on the experiment. Such variations show that it is preferable that one looks at the overall result for the whole panel and that diagnostics based on only one gene may be unreliable.
It should be noted that expression analysis can be carried out using any method for measuring gene expression. Such methods as microarrays, diagnostic panel mini-chip, PCR, real-time PCR, and other similar methods may be used. Similarly, methods for measuring protein expression may also be used.
As noted above, the cancerous prostate cells can be obtained from a patient using needle biopsy or even from prostate cancer cells present in the blood stream. Normal or non-cancerous prostate cells against which the cancerous cells can be compared can also be obtained from the patient or from other patients. Experiments have shown that the diagnosis can be possible from just a small number of cancer cells.
While it is preferable that the complete panel of 8 marker genes be used in the diagnosis of possible prostate cancer, using a subset of the 8 marker genes will also yield useful results. Using a panel of anywhere from 1 to 7 marker genes out of the 8 marker genes on suspect prostate tissue will still provide a useful indication as to whether cancerous prostate tissue may be present or whether further and more involved tests are required.
A person understanding this invention may now conceive of alternative structures and embodiments or variations of the above all of which are intended to fall within the scope of the invention as defined in the claims that follow.
| Number | Name | Date | Kind |
|---|---|---|---|
| 20030152980 | Golub et al. | Aug 2003 | A1 |
| 20040029151 | Mahadevappa et al. | Feb 2004 | A1 |
| Number | Date | Country |
|---|---|---|
| 2548528 | Jun 2006 | CA |
| WO 03012067 | Feb 2003 | WO |
| WO 03016484 | Feb 2003 | WO |
| WO 2004033727 | Apr 2004 | WO |
| WO 2004091479 | Oct 2004 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20070065856 A1 | Mar 2007 | US |
